leisure time -WSS

leisure time

author：hotspot 2025-09-28 07:22:10 - browse：513

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： The 10 drugs up first for Medicare price negotiation

WSS

A new House health package & hospitals’ new site

A new House health package & hospitals’ new site

Medicaid rebukes states for mistakenly disenrolling children

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Paxlovid rebound happens. Why and to whom are still a mystery

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Supreme Court strikes down use of affirmative action

A new House health package & hospitals’ new site

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Google's generative AI to analyze medical images — and talk to docs

Medical records are filled with copy

Trump surgeon general acknowledges mistakes during Covid

Apple is now the first public company to be valued at $3 trillion

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

explore

Trump used to be more articulate. What could explain the change?

Why Novartis is changing the name of its research labs

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

NIH nominee Bertagnolli will get October confirmation hearing

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

'Make People Better': The CRISPR babies story you probably don't know

entertainment

Wikipedia

entertainment

hotspot